Skip to main content
HR 5655 114th Congress House Health Administrative law and regulatory procedures Advisory bodies Alternative treatments Child health Congressional oversight Consumer affairs Department of Health and Human Services Drug safety, medical device, and laboratory regulation Drug therapy Drug trafficking and controlled substances Drug, alcohol, tobacco use Food and Drug Administration (FDA) Government information and archives Government studies and investigations Health personnel Health programs administration and funding Health promotion and preventive care Law enforcement administration and funding Licensing and registrations

Addiction Prevention and Responsible Opioid Practices Act

Introduced: July 7, 2016 See on congress.gov
Sign in to write a letter Sign in to watch
 Everywhere this bill has been 4 steps
Introduced
In committee
Reported out
Passed House
Passed Senate
To President
Became law
Jul 20, 2016
Referred to the Subcommittee on Health.
Jul 20, 2016
Referred to the Subcommittee on Crime, Terrorism, Homeland Security, and Investigations.
Jul 7, 2016
Referred to the Committee on Energy and Commerce, and in addition to the Committees on the Judiciary, Ways and Means, and Education and the Workforce, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.
Jul 7, 2016
Introduced in House
 Plain-English summary Congressional Research Service

Addiction Prevention and Responsible Opioid Practices Act

This bill addresses prescription opioid misuse.

The Food and Drug Administration (FDA) must: (1) seek recommendations concerning opioid drugs from an FDA advisory committee relating to the approval of a new drug that is an opioid, and the labeling of opioid drugs for pediatric prescriptions; (2) develop recommendations for education programs for prescribers of opioids; and (3) issue guidance for labeling that deters opioid abuse.

The bill amends the Federal Food, Drug, and Cosmetic Act by requiring manufacturers of opioid drugs to ensure that certain information about the risk factors associated with opioid drugs are included on the drug labels.

The bill amends the Controlled Substances Act by: (1) addressing annual narcotic manufacturing quotas with respect to fentanyl, oxycodone, hydrocodone, oxymorphone, and hydromorphone; and (2) directing the Department of Justice (DOJ) to require medical practitioners to complete a training program on prescribing opioids for chronic pain before they are certified to prescribe controlled substances in schedule II, III, or IV.

The bill establishes requirements for prescription drug monitoring systems to prevent over-prescribing controlled substances.

The Department of Health and Human Services must: (1) submit a plan of action for addressing outliers in opioid prescribing practices and ensuring an adequate response to protect the public health, and (2) study the expansion of Medicare coverage for alternatives to opioid treatments.

The bill amends the Internal Revenue Code to impose an excise tax on manufacturers or producers of opioid pain relievers. A portion of the amount generated from the tax must be used for substance abuse treatment programs.

DOJ must establish a take-back program for the safe and environmentally responsible disposal of controlled substances.

What's happening now July 20, 2016

Referred to the Subcommittee on Health.

 Committees of jurisdiction 6
 Cosponsors 1
All 1 Democratic 1